Proteasome inhibition with bortezomib: An effective therapy for severe antibody mediated rejection after renal transplantation

Clinical Nephrology

Volumn 77, Issue 3, 2012, Pages 246-253

  Sureshkumar, Kalathil K ^a   Hussain, Sabiha M ^a   Marcus, Richard J ^a   Ko, Tina Y ^a   Khan, Akhtar S ^a   Tom, Kusum ^a   Vivas, Carlos A ^a   Parris, George ^a   Jasnosz, Katherine M ^a   Thai, Ngoc L ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Antibody; Bortezomib; Donor; Mediated rejection; Specific antibody

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; COMPLEMENT COMPONENT C4D; CREATININE; FIBRIN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR4 ANTIGEN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEASOME; RITUXIMAB; TACROLIMUS; ALLOANTIBODY; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; ANAMNESIS; ANTIBODY MEDIATED GRAFT REJECTION; ANTIBODY TITER; ARTICLE; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; COLD ISCHEMIA; COLITIS; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MALE; MEMORY CELL; MICROSCOPY; NEPHRECTOMY; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; PLASMAPHERESIS; POSTOPERATIVE HEMORRHAGE; PROTEINURIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINE VOLUME; BIOPSY; BLOOD; CHRONIC KIDNEY FAILURE; DRUG ANTAGONISM; ENZYMOLOGY; HOSPITALIZATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

ADULT; BIOPSY; BORONIC ACIDS; FEMALE; GRAFT REJECTION; HUMANS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84859509851     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107156     Document Type: Article

References (13)

1. Everly MJ, Rebellato LM, Ozawa M, Briley KP, Catrou PG, Haisch CE, Terasaki PI. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation. 2010; 89: 962-967.
2. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant. 2007; 7: 402-407.
3. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dörner T, Hiepe F. Competence and competition: the challenge of becoming a longlived plasma cell. Nat Rev Immunol. 2006; 6: 741-750.
4. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005; 23: 630-639.
5. Wu J. On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosuppressants. Am J Transplant. 2002; 2: 904-912.
6. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant. 2009; 9: 201-209.
7. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007; 67: 1783-1792.
8. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008; 86: 1754-1761.
9. Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, Govil A, Roy-Chaudhury P, Alloway RR, Woodle ES. Proteasome inhibitorbased primary therapy for antibody-mediated renal allograft rejection. Transplantation. 2010; 89: 277-284.
10. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Brown E, Tevar A, Woodle ES. Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc. 2009; 41: 105-107.
11. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, Candon S, Martinez F, Snanoudj R, Rabant M, Pallet N, Nochy D, Anglicheu D, Leruez M, Loupy A, Thervet E, Hermine O, Legendre C. Bortezomib as the sole desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant. 2010; 10: 681-686.
12. Trivedi HL, Terasaki PI, Feroz A, Everly MJ, Vanikar AV, Shankar V, Trivedi VB, Kaneku H, Idica AK, Modi PR, Khemchandani SI, Dave SD. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation. 2009; 87: 1555-1561.
13. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004; 4: 349-360.